Preparation and Characterization of Gossypol Nanosuspensions

Abstract:

Article Preview

Gossypol (GP) is a kind of poorly water-soluble polyphenolic compounds. In this study, freeze dried gossypol nanosuspensions (GP-NS) were prepared by high-pressure homogenization and Freeze-drying technique. Bovine serum albumin (BSA) and D-alpha-tocopheryl polyethylene glycol succinate (TPGS) were used as stabilizing agents for the nanosuspensions while mannitol were used as lyophilized protecting medium. The physicochemical characteristics of the GP-NS were investigated when it was found that the mean particle size and zeta potential of the GP-NS were 217±23 nm and-21.4±2.7 mV, respectively, and the saturation solubility was 586.48±23.03 μg.mL-1. Differential scanning calorimetry and X-Ray Diffraction indicated that GP was in a crystalline state in nanosuspensions. GP-NS with a small particle size, and high saturation solubility, can be produced by the method described in this study.

Info:

Periodical:

Edited by:

Z.S. Liu, L.P. Xu, X.D. Liang, Z.H. Wang and H.M. Zhang

Pages:

713-720

Citation:

S. T. Yang et al., "Preparation and Characterization of Gossypol Nanosuspensions", Advanced Materials Research, Vol. 1015, pp. 713-720, 2014

Online since:

August 2014

Export:

Price:

$38.00

* - Corresponding Author

[1] Kenar JA. Reaction chemistry of gossypol and its derivatives. JAOCS. 2006; 83(4): 269-302.

[2] Wu YW, Chik CL, Knazek RA. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res. 1989; 49: 3754-3758.

[3] Royer RE, Deck LM, Vander Jagt TJ, Marinez FJ, Mills RG, Young SA, Vander Jagt DL. Synthesis and anti-HIV activity of 1, 1'-dideoxygossypol and related compounds. J Med Chem. 1995; 38: 2427-2432.

[4] Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002; 19: 189-94.

[5] Nyström C. Dissolution properties of soluble drugs: theoretical background and possibilities to improve the dissolution behaviour. In: Müller RH, Benita S, Böhm B, editors. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Stuttgart: Medpharm Scientific Publishers, 1998. 143-147.

DOI: https://doi.org/10.1016/s0378-5173(00)00604-9

[6] Nyström C, Saers S. Solid dispersions for fast release and dissolution of drug with low aqueous solubility in formulation of poorly available drugs for oral administration. European Symposium, Paris, 5-6 February APGI Swedish Academy of Pharmaceutical Sciences, 1996. 94-103.

[7] Simonelle AP, Metha SC, Higuchi WI. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. J Pharm Sci.

[8] Grant DJW, Brittain. HG. Solubility of pharmaceutical solids. In: Brittain HG (ed. ) Physical characterization of pharmaceutical solids. Marcel Dekker, New York, 1995. 321-86.

[9] Müller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of dissolution. United States Patent No: 5858410, (1999).

[10] Müller RH, Jacobs C, Kayser O. Nanosuspensions for the Formulation of Poorly Soluble Drugs In: Nielloud F, Marti-Mestres G, editors. Pharmaceutical Emulsions and Suspensions. Marcel Dekker, New York, 2000. pp.383-407.

[11] Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm. 2009; 380: 216-22..

[12] Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010; 399: 129-39.

[13] Moschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm. 2004; 58: 615-19.

[14] Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm. 2008; 350: 338-43.

[15] Krause KP, Kayser O, Mader K, Gust R, Müller RH. Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int J Pharm. 2000; 196: 169-72.

DOI: https://doi.org/10.1016/s0378-5173(99)00414-7

[16] Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil R M. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm. 2007; 340: 126-33.

DOI: https://doi.org/10.1016/j.ijpharm.2007.03.011

[17] Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006; 62: 3-16.

DOI: https://doi.org/10.1016/j.ejpb.2005.05.009

[18] Mishra PR, Al Shaal L, Müller RH, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm. 2009; 371: 182-9.

[19] Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001; 47: 3-19.

[20] Müller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size reduction technique. Int J Pharm. 1998; 160: 229-37.

[21] Mersmann A, Eble A, Heyer C. Crystal Growth: Crystallization technology handbook. In: Mersmann A editor (2nd ed). New York: Taylor & Francis; 2001. 102-9.

DOI: https://doi.org/10.1201/9780203908280-4

[22] Schmidt M, Kusche R, Issendorff BV, Haberland H. Irregular variations in themelting point of size-selected atomic clusters. Nature. 1998; 393: 238-40.